Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sanofi SA (NASDAQ:GCVRZ)

0.1808
Delayed Data
As of 3:55pm ET
 +0.0092 / +5.36%
Today’s Change
0.06
Today|||52-Week Range
0.75
+60.71%
Year-to-Date
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
4:40pm / Zacks.com - Paid Partner Content
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
May 24 / Zacks.com - Paid Partner Content
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
11:05am / Zacks.com - Paid Partner Content
Novartis' Cardiovascular Drug Gets Positive Recommendation
May 23 / Zacks.com - Paid Partner Content
5 Things You Need to Know About Zika Virus
9:26am / MotleyFool.com - Paid Partner Content
Endonovo Therapeutics: Innovative Treatment, Catalyst Create Compelling Opportunity
May 23 / GuruFocus News - Paid Partner Content
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
May 25 / Zacks.com - Paid Partner Content
Here's What Pfizer's Telling Us About Biotech M&A
May 21 / MotleyFool.com - Paid Partner Content
European Markets End in Positive Territory; Rally for Second Day
May 25 / TheStreet.com - Paid Partner Content
Better Buy: MannKind Corp. vs. Dexcom
May 20 / MotleyFool.com - Paid Partner Content
Sanofi Moves to Oust Medivation Board
May 25 / TheStreet.com - Paid Partner Content
Better Buy: Regeneron Pharmaceuticals, Inc. vs. Ophthotech
May 17 / MotleyFool.com - Paid Partner Content
Lilly's (LLY) R&D Update, Targets 20 New Launches by 2023
May 25 / Zacks.com - Paid Partner Content
Inovio Pharmaceuticals' Zika Vaccine Takes a Big Step Forward
May 17 / MotleyFool.com - Paid Partner Content
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
May 24 / Zacks.com - Paid Partner Content
5 Growth Stocks to Buy in May
May 14 / MotleyFool.com - Paid Partner Content
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.
May 24 / MotleyFool.com - Paid Partner Content
Aegerion Enters into Settlement Agreement with DoJ and SEC
May 13 / Zacks.com - Paid Partner Content
Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Wh...
May 24 / MotleyFool.com - Paid Partner Content
Stocks: 5 things to know before the open
Apr 28 / CNNMoney.com